Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00117598 · ClinicalTrials.gov registry record · Phase 3
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 169
- Enrollment target
NCT00117598: Completed Phase 3 study, sponsored by Pfizer.
NCT00117598 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 169 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00117598, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 169 participants
- Enrollment target
Study Summary
This is an open-label, randomized trial in relapsed refractory subjects with mantle cell lymphoma (MCL).
Primary Outcome
The period from randomization until disease progression, death or date of last contact.
Interventions
- DRUG Investigator's choice
- DRUG Temsirolimus (CCI-779)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 169 participants |
| Start Date | 2005-05 |
| Est. Completion | 2011-01 |
| Phase | Phase 3 |
What the finished NCT00117598 record still lists
NCT00117598 is an interventional study that assigns participants to a tested intervention. The registered 169 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (78% lower).
The record links to 0 conditions, and to 2 interventions - of which Investigator's choice is the first listed.
NCT00117598 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00117598 about?
NCT00117598 is a clinical study titled "Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)". This is an open-label, randomized trial in relapsed refractory subjects with mantle cell lymphoma (MCL).
What is the current status of trial NCT00117598?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 169 participants. The study started on 2005-05. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00117598?
The interventions under investigation include: Investigator's choice (DRUG), Temsirolimus (CCI-779) (DRUG).
Who is sponsoring clinical trial NCT00117598?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00117598's enrollment target sits among peer trials
169 1459th of 2000 higher than 542 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06191484 · 169 participants · NA
Risk and Resilience to Suicide Following Late-Life Spousal Bereavement
- NCT02016430 · 170 participants · NA
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
- NCT02621021 · 170 participants · Phase 2
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- NCT04094701 · 170 participants · NA
Hip Arthroscopy Postoperative Opioid Demands
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia